导师罗志军
罗志军简历
罗志军教授，博士，江西省赣鄱英才“555”特聘教授，中国生物物理学会脂质代谢与生物能学分会委员，南昌大学玛丽女王学院院长，江西省肿瘤病原学及分子病理学重点实验室负责人。
1983年毕业于江西医学院临床医学系，获学士学位，1986年获中山大学医学遗传学硕士，1991年毕业于美国爱因斯坦医学院，获博士学位。其后在哈佛大学完成博士后训练，曾在博士顿大学医学院担任副教授。
罗志军教授长期致力于研究蛋白质磷酸化对细胞生长和代谢的调控，揭示调控异常如何导致肿瘤和代谢综合征之类的疾病。他是首先发现能量代谢关键酶-AMPK抑制肿瘤细胞的蛋白质、脂质合成从而抑制其生长的学者之一，并提出了AMPK可作为代谢性肿瘤抑制因子的假说。这一学说逐步被同行认可并导致若干药物公司以AMPK作为肿瘤治疗的靶点。共发表SCI 科研论文近80篇，其中包括Nature, Cell Metabolism, PNAS, Diabetes，EMBO journal，Molecular and Cellular Biology, Journal of Biological Chemistry, FASEB Journal, Trends in Pharmaceutical Sciences, Oncogene等著名杂志，总引用率超过7300多次(https://scholar.google.com/citations?hl=en&user=HbyMZ0IAAAAJ)，近5年(Since 2013)的总引用率超过3250 余次。担任过国际著名杂志《Journal Biological Chemistry》的编委，并时常被邀请为国际重要杂志审稿，曾获得美国国立卫生研究院科研经费300万美元，完成国家自然基金面上项目2项，在研国家自然科学基金面上、地区项目各1项、赣鄱英才555工程项目共450万。此外，担任过美国NIH科研基金委员会评委，常被邀请为外国科研基金担任临时评审人。获美国发明专利两项。
教育经历
1983年8月 医学学士， 江西医学院， 江西省南昌市。.
1986年8月 医学遗传学硕士，中山医科大学，广东省广州市。
1991年9月 理学博士，美国爱因斯坦医学院（Albert Einstein College of Medicine）， 美国纽约。
工作经历
1986年9月至1987年1月 江西大学生物系，教师。
1991年10月至1992年10月 博士后，医学系，爱因斯坦医学院。.
1992年11月至1994年12月 博士后, 哈佛大学医学院麻省总医院医学系糖尿病科，美国马萨诸塞州，波士顿市.
1995年1月至1997年8月 讲师，哈佛大学医学院麻省总医院医学系糖尿病科，美国马萨诸塞州，波士顿市
1997年9月至2006年5月 助理教授，波士顿大学医学院医学系，美国马萨诸塞州，波士顿市。
2006年5月至2018年5月 副教授，波士顿大学医学院，美国马萨诸塞州，波士顿市。
2011年3月至2014年5月 教授，南昌大学医学院副院长、基础医学院院长。
2015年至今 教授，南昌大学玛丽女王学院院长。
荣誉与社会活动
1993年–1996年 National Research Service Award, NIH 5F32CA063790, Postdoctoral fellowship。
学术团体：
1994年至今 会员，Advanced American Association of Science, USA。
1997年至今 会员，American Diabetes Association, USA。
1997年至今 会员，American Society for Biochemistry and Molecular Biology (ASBMB), USA。
2010年 会员，American Association of Cancer Research, USA。.
2018年 中国生物物理学会脂质代谢与生物能学分会委员
荣誉兼职：
2002年至今 顾问，Mercury Therapeutics, Inc (药物公司), Woburn, MA， USA。.
2006年至2010年 客座教授，北京大学医学部基础医学院。.
2008至2013年 编委，Journal of Biological Chemistry （美国著名生物化学杂志）。.
特邀为以下杂志审稿： EMBO Journal, Oncogene, Diabetes, American Journal of Pathology, Molecular Endocrinology, FASB letter , PLOS One， Oncogene, Endocrinology, Oncotarget, Molecular Pharmacology, Endocrine-related Cancer等。
专利
1. 共同发明人，Title: Inhibiting Protein Interactions, U.S. Patent Number: 6,103,692. 该专利已被Mercury Therapeutic, Inc. （美国药物公司）购买。
2. 共同发明人，Title: Method of Inhibiting Choroidal Neovascularization. Application No. US Patent Office: 20050187241。 该专利已被Santen Pharmaceutical购买，完成了临床三期试验。
发表的文章
1. Luo ZJ, Du CS, Yu BJ, Liang YQ, Tokunaga K, and Omoto K. Genetic Polymorphism of Properdin Factor B (BF) in Chinese Patients with two types of Diabetes Mellitus. Japanese. J. Human Genet. 31: 259-262, 1986.
2. Luo ZJ and Du, CS. Genetic Polymorphism of Properdin Factor B in the Guangzhouese Population. J. Genetics and Genomics 14: 481-485, 1987
3. Luo ZJ, Du CS, Tokunaga K, and Omoto, K. Genetic polymorphism of properdin factor B (BF) in a Chinese population: existence of two rare variants. Japanese. J. Human Genet. 32: 33-38, 1987.
4. Omoto K, Tokunaga K, Zeng Z, Du RF, Zhao H, Jin F, Du CS, and Luo ZJ. Population genetic-studies of national minority-groups in Hainan-Island, China – Polymorphisms of complement systems. Japanese. J. Human Genet. 33: 253-253, 1988.
5. Luo ZJ, Shafit-Zagardo B, and Erlichman J. Identification of the MAP2 and P75 binding domain in the regulatory subunit (RIIß) of type II cAMPdependent protein kinase: cloning and expression of the cDNA for bovine brain RIIß. J. Biol. Chem. 265: 21804-21810, 1990.
6. Singh IS, Luo ZJ, Eng A, and Erlichman, J. Molecular cloning and characterization of the promoter region of the mouse regulatory subunit RIIß of type II cAMP-dependent protein kinase. Biochem. Biophys. Res. Commun. 178: 221-226, 1991.
7. Luo ZJ, Singh IS, Fujihira T, and Erlichman, J. Characterization of a minimal promoter element required for transcription of the type IIß regulatory subunit (RIIß) of cAMP-dependent protein kinase. J. Biol. Chem. 267: 24738-24747, 1992.
8. Keryer G, Luo Z, Cavadore JC, Erlichman J, and Bornens, M. Phosphorylation of the regulatory subunit of type IIß cAMP-dependent protein kinase by cyclin B/p34cdc2 kinase impairs its binding to microtubule-associated protein 2. Proc. Natl. Acad. Sci. USA. 90: 5418-5422, 1993.
9. Singh IS, Luo Z, Kozlowski MT, and Erlichman, J. Association of USF and c-Myc with a helix-loop-helix-consensus motif in the core promoter of the murine type IIß regulatory subunit gene of cAMP-dependent protein kinase. Molecular Endocrinology. 8: 1163-1174, 1994.
10. Luo ZJ, Zhang X, Rapp U, and Avruch J. Identification of the 14.3.3 zeta domains important for self association and Raf binding. J. Biol. Chem. 270: 23681-23687, 1995.
11. Si J, Luo Z, and Mei L. Induction of acetylcholine receptor gene expression by ARIA requires activation of MAP kinase. J. Biol. Chem. 271: 19752-19759, 1996.
12. Luo Z, Tzivion G, Belshaw PJ, Vavvas D, Marshall M, and Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383: 181-185, 1996 [see comments].
13. Luo Z, Diaz B, Marshall M, and Avruch J. An intact Raf zinc finger is required for optimal binding to processed Ras, and for Ras-dependent Raf activation in situ. Mol. Cell. Biol. 17: 46-53,1997.
14. Marti A, Luo ZJ, Cunningham C, Ohta Y, Hartwig J, Stossel T, Kyriakis J, and Avruch J. ABP-280 binds the SAPK activator SEK-1, and is required for TNFa activation of SAPK in melanoma cells. J. Biol. Chem. 272: 2620-2628, 1997.
15. Tzivion G, Luo Z, and Avruch J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394: 88-92, 1998.
16. Peng M, Li Y, Luo Z, Liu C, Laties AM, and Wen R. a2-Adrenergic agonists selectively activate extracellular signal-regulated kinase in Muller cells in vivo. Investigative Ophthalmology & Visual Science 39: 1721-6, 1998.
17. Kurowski TG, Lin Y, Luo ZJ, Tschlis PN, Buse MG, Heydrick SJ, and Ruderman N. Hyperglycemia inhibits insulin activation of AKT/protein kinase B but not phosphatidylinositol 3-kinase in Raf skeletal muscle. Diabetes 48: 658-63, 1999.
18. Tzivion G, Luo ZJ, and Avruch, J. Calyculin A induced vimentin phosphorylation sequesters 14-3-3 and displaces other 14-3-3 partners in vivo. J. Biol. Chem. 275: 29772-29778, 2000.
19. Lenz G, Gottfried C, Luo Z, Avruch J, Rodnight R, Nie WJ, Kang Y, and Neary JT. P2Y purinoceptor subtypes recruit different Mek activators in astrocytes. British J. Pharmacology 129: 927-936, 2000.
20. Hayne C, Tzivion G, and Luo Z. Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole. J. Biol. Chem. 275:31876-31882, 2000.
21. Lenz G, Goncalves D, Luo Z, Avruch J, Rodnight R, Neary JT. Extracellular ATP stimulates an inhibitory pathway towards growth factor-induced cRaf-1 and MEKK activation in astrocyte cultures. J. Neurochem. 77:1001-9, 2001.
22. Avruch J, Khokhlatchev A, Kyrakis JM, Luo Z, Tzivion G, Vavvas D, and Zhang X-F. Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res. 56: 127-55, 2001.
23. Lin Y, Itani S, Dean DJ, Kurowski TG, Luo ZJ, Yaney GC, and Ruderman NB. Inhibition of insulin signaling and glycogen synthesis by phorbol dibutyrate in rat skeletal muscle. Am. J. Physiol. 281: E8-E15, 2001.
24. Zang M, Waelde CA, Xiang X, Rana A, Wen Rong, and Luo Z. Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1. J. Biol. Chem. 276: 25157-25165, 2001.
25. Zang M, Hayne C, and Luo Z. Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J. Biol. Chem. 277: 4395-4405, 2002.
26. Xiang X, Yuan M, Ruderman N, and Luo Z. 14-3-3 facilitates insulin-stimulated dissociation of IRS-1 from high speed pellet fraction. Mol. End. 16: 552-562, 2002.
27. Xu C. W. and Luo Z. Inactivation of Ras function by allele-specific peptide aptamers. Oncogene 21: 5753-5757, 2002.
28. Xiang X, Zang M, Waelde CA, Wen R, and Luo Z. Phosphorylation of S338SYY341 regulates specific interaction between Raf-1 and MEK1. J. Biol. Chem 277: 44996-45003, 2002.
29. Luo ZG, Wang Q, Zhou JZ, Wang JB, Luo Z, Liu M, He X, Wynshaw-Boris A, Xiong WC, Lu B, and Mei L. Regulation of AchR clustering by Dishevelled interacting with MuSK and Pak1. Neuron. 35: 489-505, 2002.
30. Huang YZ, Zang M, Xiong WC, Luo Z, and Mei L. Regulation of growth factor-induced Erk activation by Erbin interacting with active Ras. J. Biol. Chem. 278: 1108-1114, 2003.
31. Tomas E, Lin YS, Dagher Z, Saha A, Luo Z, Ido Y, Ruderman NB. Hyperglycemia and insulin resistance: possible mechanisms. Ann N Y Acad Sci 967: 43-51, 2002.
32. Song Y, Zhao L, Tao W, Laties AM, Luo Z and Wen R. Photoreceptor protection by cardiotrophin-1 in transgenic Rats with the Rhodopsin mutation S334ter. Investigative Ophthalmology & Visual Science 44: 4069-4075, 2003.
33. Cai D, Iyer A, Near RI, Felekkis KN, Luo Z, Albanese C, Pestell RG, and Lerner A. AND-34/BCAR3, a GDP exchange factor whose over-expression confers anti estrogen resistance, activates Rac and Cdc42 signaling pathway. Cancer Research 63: 6802-6808, 2003.
34. Tomas E, Kelly M, Xiang KX, Tsao T-S, Keller C, Keller P, Luo Z, Lodish H, Saha AK, Unger R, Ruderman NB. Metabolic and hormonal interactions between muscle and adipose tissue. Proc. Nutr. Soc. 63: 381-5, 2004.
35. Kelly M, Keller C, Avilucea P, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun. 320: 449-54, 2004.
36. Xiang X, Saha AK, Wen R, Ruderman NB, and Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 321: 161-167, 2004.
37. Hayne C, Xiang X, Luo Z. MEK inhibition and phosphorylation of serine 4 on B23 are two coincident events in mitosis. Biochem. Biophys. Res. Comm. 321: 675-680, 2004.
38. Luo Z, Saha AK, Xiang X, and Ruderman NB. AMPK, the metabolic syndrome and cancer. TIPS 26: 69-76, 2005.
39. Zhu J, Balan V, Bronisz A, Balan K, Sun H, Leicht DT, Luo Z, Qin J, Avruch J, and Tzivion G. Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding. Mol Biol Cell 16:4733-44, 2005.
40. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N. Free fatty acids produce insulin resistance and activate the proinflammatory NFkB pathway in rat liver. Diabetes 54:3458-65 2005.
41. Jin Y, Dai M-S, Lu, SZ, Xu Y, Luo Z, Zhao Y, and Lu H. 14-3-3g associates with MDMX that is phosphorylated by UV-activated ChK1, resulting in p53 activation. EMBO J 25: 1207-18, 2006.
42. Chadee DN, Hung G, Andalibi A, Lim DJ, Luo Z, Gutmann DH, and Kyriakis KM. MLK3 regulates B-Raf through a mechanism that involves maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc. Natl. Acad. Sci. 103: 4463-68, 2006.
43. He M, Zhang J, Shao L, Huang Q, Chen J, Chen H, Chen X, Liu D, Luo Z. Upregulation of 14-3-3 isoforms in acute rat myocardial injuries induced by burn and lipopolysaccharide. Clinical and Experimental Pharmacology and Physiology 33: 374–80, 2006.
44. Park S, Rath O, Beach S, Xiang X, Kelly SM, Luo Z, Kolch W, Yeung KC. Regulation of RKIP binding to the N-region of the Raf-1 kinase. FEBS Lett. 580:6405-12, 2006.
45. Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, Giralt M, Ritov VB, Menshikova EV, Kelley DE, Hidalgo J, Pedersen BK, Kelly M. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55 Suppl 2:S48-54, 2006.
46. Guo W, Wong S, Xie W, Lei T, Luo Z. Palmitate Modulates Intracellular Signaling, Induces Endoplasmic Reticulum Stress, and Causes Apoptosis in Mouse 3T3-L1 and Rat Primary Preadipocytes. Am J Physiol Endocrinol Metab. 293:E576-86, 2007.
47. Chakrabarti P, Anno T, Manning BD, Luo Z, and Kandror KV. The mTOR complex 1 regulates leptin biosynthesis in adipocytes at the level of translation. The role of the 5'-UTR in the expression of leptin mRNA. Mol Endol 22: 2260-7, 2008.
48. Wang L, Persons KS, Jamieson D, Flanagan JN, Hsu HH, Holick MF, Luo Z, Sakaki T, Urushino N, Faller DV, Chen TC Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Anticancer research 28:2009-13, 2008
49. Zang M, Gong J, Luo L, Zhou J Xiang X, Huang W, Huang Q, Luo X, Olbrot M, Peng Y, Chen C, Luo Z. Characterization of S338 phosphorylation in Raf-1 activation. J Biol Chem, 283: 31429-37, 2008.
50. Zhou J, Huang W, Tao R, Ibaragi R, Lan L, Ido Y, Wu X, Alekseyev Y, Lendburg M, Hu G-F, Luo Z. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 28: 1993-2002 2009.
51. Chen Y, Wang R, Kun Z, Kwak Y-D, Liu Y, Ma T, Thompson RC, Zhao YB, Gasparini L, Luo Z, Xu H, Liao F-F. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via upregulating BACE1 transcription. Proc. Natl. Acad. Sci. 106:3907-12, 2009.
52. Ma T, Zhao Y, Kwak YD, Yang Z, Thompson R, Luo Z, Xu H, Liao FF. Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J Neurosci. 29:11226-36, 2009
53. Tao R, Gong J, Luo X, Zang M, Guo W, Wen R, Luo Z. AMPK exerts dual regulatory effects on the PI3K pathway. J Mol Signal. 5: 1-9. 2010, PMC PMC 2848036.
54. Luo Z, Zang M, Guo W. AMP-activated protein kinase - metabolic tumor suppressor: control of metabolism and cell growth. Future Oncology 6:457-70, 2010, PMC: 2854547.
55. Zhang H, Feng H, Luo L, Zhou Q, Luo Z, Peng Y. Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2. Virus Res. 150: 22-27, 2010, PMC2860046.
56. Zhou J, Yang Z, Tsuji T, Gong J, Xie J, Chen C, Li W, Amar S, Luo Z. LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene, 30: 1892-900.2011, PMID: 21217782.
57. Li W, Zhou J, Chen L, Luo Z, Zhao Y. Lysyl Oxidase, A Critical Intra- and Extra-Cellular Target in the Lung for Cigarette Smoke Pathogenesis. Int. J. Environ. Res. Public Health 8: 161-184, 2011, doi:10.3390/ijerph8010161.
58. Li Y, Xu S, Mihaylova M, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E,. Shyy J Y-J , Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin resistant Mice. Cell Metabolism. 13:376-88, 2011, PMID: 21459323.
59. Li Y, Xu S , Giles A, Nakamura K, Lee JW, Hou X, Donmez G, Li J, Luo Z, Kenneth W, Guarente L, Zang M. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. 25: 1664-79, 2011, PMID: 21321189.
60. Chakrabarti P, English T, Karki S, Tao R, Luo Z, Farmer S, Kandror KV. Sirt1 controls lipolisys in adipocytes via foxo1-mediated expression of ATGL. J Lipid Res. 52: 1693-701, 2011. PMID: 21743036.
61. Wang B, Zhang H, Zhu M, Luo Z, Peng Y. MEK1-ERKs signal cascade is required for the replication of Enterovirus 71 (EV71). Antiviral Res. 93: 110-7, 2012, PMID: 22101247.
62. Luo L, Huang W, Tao R, Hu N, Xiao ZX, Luo Z. ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis. Cancer Lett. 328:114-9, 2013. PMID: 22960274.
63. Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ, Lu NH. Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: A novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol. 37: 72-9, 2013. PMID: 22521126
64. He G, Zhang YW, Lee JH, Zeng SX, Wang YV, Luo Z#, Dong XC, Viollet B, Wahl GM, Lu H. AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol. Cell. Biol 34: 148-57, 2014
65. He H, Ke R, Lin H, Ying Y, Liu D, Luo Z#. Metformin, an old drug, brings a new era to cancer therapy. The Cancer journal 21：70-74, 2015, PMID: 25815846. Invited review.
66. Luo L, Jiang S, Huang D, Lu N, Luo Z#. MLK3 phosphorylates AMPK independently of LKB1. PloS One 10(4):e0123927. PMID: 25874865, 2015
67. Li NS, Zou JR, Lin H, Ke R, He XL, Xiao L, Huang D, Luo L, Lv N, Luo Z#. LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells. Tumour Biol. 2015. PMID: 26718214.
68. Lin H, Li N, He H, Ying Y, Sunkara S, Luo L, Lv N, Huang D, Luo Z#. AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition. Mol Pharmacol. 88(6):1062-71. 2015. PMID: 26424816.
69. Yang Z, Xie C, Xu W, Liu G, Cao X, Li W, Chen J, Zhu Y, Luo S, Luo Z, Lu N. Phosphorylation and inactivation of PTEN at residues Ser380/Thr382/383 induced by Helicobacter pylori promotes gastric epithelial cell survival through PI3K/Akt pathway. Oncotarget. 6(31):31916-26. PMID: 26376616, 2016
70. Huang D, He X, Zou J, Guo P, Jiang S, Lv N, Alekseyev Y, Luo L, Luo Z#. Negative regulation of Bmi-1 by AMPK and implication in cancer progression. Oncotarget. 7(5):6188-200. 2016. PMID: 26717043.
71. He H, Liu D, Lin H, Jiang S, Ying Y, Shao C, Deng D, Zaia J, Wen R, Luo Z#. Phosphatidylethanolamine binding protein 4 (PEBP4) is a secreted protein and has multiple functions. BBA Mol Cell Res 1863(7 Pt A):1682-1689. 2016. PMID: 27033522
72. He C, Yang Z, Cheng D, Xie C, Zhu Y, Ge Z, Luo Z, Lu N. Helicobacter pylori Infection Aggravates Diet-induced Insulin Resistance in Association With Gut Microbiota of Mice. EBioMedicine. 12:247-254. 2016. PMID: 27743904
73. Wang Y, Li Y, Hu G, Huang X, Rao H, Xiong X, Luo Z, Lu Q, Luo S. Nek2A phosphorylates and stabilizes SuFu: A new strategy of Gli2/Hedgehog signaling regulatory mechanism. Cell Signal. 28(9):1304-13. 2016. PMID: 27297360
74. Liang Z, Li W, Liu J, Li J, He F, Jiang Y, Yang L, Li P, Wang B, Wang Y, Ren Y, Yang J, Luo Z, Vaziri C, Liu P. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Sci Rep. 7:41776. 2017. PMID: 28150753
75. Li J, Liu J, Liang Z, He F, Yang L, Li P, Jiang Y, Wang B, Zhou C, Wang Y, Ren Y, Yang J, Zhang J, Luo Z, Vaziri C, Liu P. Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Cell Death Dis. 8:e2673. 2017. PMID: 28300827
76. Ying Y, Ueta T, Jiang S, Lin H, Wang Y, Vavvas D, Wen R, Chen YG, Luo Z#. Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK. Oncotarget. 8:32794-806. 2017. PMID: 28427181.
77. Lin H, Ying Y, Wang YY, Wang G, Jiang SS, Huang D, Luo L, Chen YG, Gerstenfeld LC, Luo Z#. AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation. BBA Mol Cell Res 1864(12):2369-2377. 2017. PMID: 28847510.
78. Wang H, Zhu C, Ying Y, Luo L, Huang D, Luo Z#. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget. 9:10135-10146. 2018
79. Gao J, Ye J, Ying Y, Lin H, Luo Z#. Negative regulation of TGF-β by AMPK and implications in the treatment of associated disorders.
Acta Biochim Biophys Sin. 2018 Jun 1;50(6):523-531. doi: 10.1093/abbs/gmy028.
科研基金
在研:
01/01/17-12/31/21 31660332 国家自然科学基金地区科学基金项目
单磷酸腺苷活化蛋白激酶羧基端S/T-区域磷酸化负调节及其在
肿瘤转移中的作用
01/01/16-12/31/20 81572753 国家自然科学基金面上项目
结题:
01/01/13-12/31/16 81272926 国家自然科学基金面上项目
题目：AMPK对TGFbeta信号转导和乳腺癌转移的抑制作用。
04/01/14-07/31/16 1R21EY024388-01(PI) National Institute of Health
AMPK regulates angiogenesis by inhibition of the ALK1 signaling pathway
Objective: This grant delineates the mechanism by which AMPK phosphorylation of ALK1, leading to inhibition of angiogenesis. Outcome of the proposed studies will lead to expand the use of AMPK activators in treatment of retinopathy, a blindness complication of type 2 diabetes and tumor angiogenesis.
01/01/12-12/31/15 81171952 国家自然科学基金面上项目
题目：LITAF的肿瘤抑制作用
09/01/06-08/31/12 R01 CA118918 (PI) National Institute of Health.
Title: The fuel sensing enzyme AMPK in the pathogenesis of prostate cancer.
Objective: This project explores if AMPK functions as a metabolic tumor suppressor and the mechanism by which AMPK inhibits the growth of prostate cancer cells.
Role: Principal investigator.
12/01/05-11/30/11 R01 DK19514 (CoI) National Institute of Health.
Title: Nutrition and Hormonal Regulation of AMPK and Malonyl CoA.
Objective: This project is to investigate the regulation of the AMPK and malonyl CoA by nutrients and hormones. It is relevant to public health, since dysregulation of the AMPK and malonyl CoA network has been linked to the pathogenesis of the metabolic syndrome and may be a target for its treatment and prevention.
Role: Co-investigator.
09/01/098-1/31/10 R01 GM057959 (PI) National Institute of Health.
Mechanisms of Raf-1 activation.
Objective: This grant supports studies of the mechanism by which Raf-1 is regulated by phosphorylation, dimerization, Ras and 14-3-3. This grant will not be finished on time and will ask for no cost extension.
Role: Principal investigator.
4/98-3/00 Recipient of Grant from Boston Obesity and Nutrition Center (BONRC), 2P30DK46200, PI. Title: Role of the MAPK family in insulin resistance.
1/99-12/02 PI, Research Award from American Diabetes Association, PI. Title: Regulation of IRS-1 by 14-3-3 in adipocytes.